CL2012003206A1 - Proceso para preparar derivados de n-bifenil-ilmetil-2-[2-(bencilsulfanil)-4-oxo-ciclopenta[d]pirimidin]acetamida; los compuestos intermediarios considerados; y los procesos de preparación de los intermediarios. - Google Patents

Proceso para preparar derivados de n-bifenil-ilmetil-2-[2-(bencilsulfanil)-4-oxo-ciclopenta[d]pirimidin]acetamida; los compuestos intermediarios considerados; y los procesos de preparación de los intermediarios.

Info

Publication number
CL2012003206A1
CL2012003206A1 CL2012003206A CL2012003206A CL2012003206A1 CL 2012003206 A1 CL2012003206 A1 CL 2012003206A1 CL 2012003206 A CL2012003206 A CL 2012003206A CL 2012003206 A CL2012003206 A CL 2012003206A CL 2012003206 A1 CL2012003206 A1 CL 2012003206A1
Authority
CL
Chile
Prior art keywords
benzylsulfanyl
cyclopenta
pyrimidin
ylmethyl
acetamide
Prior art date
Application number
CL2012003206A
Other languages
English (en)
Spanish (es)
Inventor
Claire Frances Crawford
Suzanne Helen Davies
Charles Edward Wade
Kevin Stuart Cardwell
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44992024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012003206(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CL2012003206A1 publication Critical patent/CL2012003206A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/04Formation of amino groups in compounds containing carboxyl groups
    • C07C227/06Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/04Formation of amino groups in compounds containing carboxyl groups
    • C07C227/06Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid
    • C07C227/08Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid by reaction of ammonia or amines with acids containing functional groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/48Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CL2012003206A 2010-05-17 2012-11-16 Proceso para preparar derivados de n-bifenil-ilmetil-2-[2-(bencilsulfanil)-4-oxo-ciclopenta[d]pirimidin]acetamida; los compuestos intermediarios considerados; y los procesos de preparación de los intermediarios. CL2012003206A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34522410P 2010-05-17 2010-05-17

Publications (1)

Publication Number Publication Date
CL2012003206A1 true CL2012003206A1 (es) 2013-01-25

Family

ID=44992024

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012003206A CL2012003206A1 (es) 2010-05-17 2012-11-16 Proceso para preparar derivados de n-bifenil-ilmetil-2-[2-(bencilsulfanil)-4-oxo-ciclopenta[d]pirimidin]acetamida; los compuestos intermediarios considerados; y los procesos de preparación de los intermediarios.

Country Status (25)

Country Link
US (2) US9447052B2 (enExample)
EP (1) EP2571857B1 (enExample)
JP (1) JP6027529B2 (enExample)
KR (1) KR20130089157A (enExample)
CN (2) CN103003249B (enExample)
AR (1) AR081399A1 (enExample)
AU (1) AU2011256270B2 (enExample)
BR (1) BR112012030532A2 (enExample)
CA (1) CA2799520C (enExample)
CL (1) CL2012003206A1 (enExample)
CO (1) CO6630197A2 (enExample)
CR (1) CR20120630A (enExample)
DO (1) DOP2012000289A (enExample)
EA (1) EA026569B1 (enExample)
IL (1) IL223068A0 (enExample)
MA (1) MA34301B1 (enExample)
MX (1) MX2012013387A (enExample)
NZ (1) NZ603672A (enExample)
PE (1) PE20130318A1 (enExample)
PH (1) PH12012502247A1 (enExample)
SG (1) SG185559A1 (enExample)
TW (1) TW201209043A (enExample)
UY (1) UY33388A (enExample)
WO (1) WO2011146494A1 (enExample)
ZA (1) ZA201208631B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33388A (es) * 2010-05-17 2011-12-01 Glaxo Group Ltd Nuevos procesos para la preparacion de compuestos de pirimidinona
WO2015087239A1 (en) 2013-12-11 2015-06-18 Ranbaxy Laboratories Limited Processes for the preparation of darapladib and its intermediates
WO2015092687A2 (en) 2013-12-17 2015-06-25 Ranbaxy Laboratories Limited Process for the purification of darapladib
US11583596B2 (en) 2017-09-26 2023-02-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Radiolabeled Darapladib and analogs thereof and their use as imaging compounds
US10866963B2 (en) * 2017-12-28 2020-12-15 Dropbox, Inc. File system authentication

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1143516B (de) 1961-04-27 1963-02-14 Bayer Ag Verfahren zur Herstellung von Peptiden
US4277465A (en) 1978-08-26 1981-07-07 Kyoto Yakuhin Kogyo Kabushiki Kaisha Adjuvant for promoting absorption of therapeutically active substances through the digestive tract
US4235776A (en) * 1979-03-15 1980-11-25 Eli Lilly And Company Tetrahydro-2H-benzo[c]pyrroles
DE2941597A1 (de) * 1979-10-13 1981-04-23 Basf Ag, 6700 Ludwigshafen Piperidinderivate von 4,5-dialkyl-3-hydroxy-pyrrol-2-carbonsaeureestern, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
US4619941A (en) * 1984-11-19 1986-10-28 American Cyanamid Company N-[(1H-imidazol-1-yl)alkyl]-1H-indolecarboxamides useful as thromboxane synthetase inhibitors and antihypertensive agents
JP2001522844A (ja) * 1997-11-06 2001-11-20 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ピリミジノン化合物およびそれを含有する医薬組成物
US6750228B1 (en) 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US6503745B1 (en) 1998-11-05 2003-01-07 Biocryst Pharmaceuticals, Inc. Cyclopentane and cyclopentene compounds and use for detecting influenza virus
PT1175408E (pt) 1999-05-01 2005-04-29 Smithkline Beecham Plc Derivados sulfonamida
BRPI0108396B1 (pt) * 2000-02-16 2015-05-19 Smithkline Beecham Plc Derivados de pirimidina-4-ona como inibidores de ldl-pla2
GB0119795D0 (en) * 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel process
UY33388A (es) * 2010-05-17 2011-12-01 Glaxo Group Ltd Nuevos procesos para la preparacion de compuestos de pirimidinona

Also Published As

Publication number Publication date
KR20130089157A (ko) 2013-08-09
SG185559A1 (en) 2012-12-28
EP2571857B1 (en) 2017-08-23
EP2571857A4 (en) 2013-11-20
UY33388A (es) 2011-12-01
AU2011256270B2 (en) 2015-11-26
CO6630197A2 (es) 2013-03-01
MX2012013387A (es) 2012-12-10
JP6027529B2 (ja) 2016-11-16
IL223068A0 (en) 2013-02-03
AU2011256270A1 (en) 2012-12-20
TW201209043A (en) 2012-03-01
US9725420B2 (en) 2017-08-08
EA026569B1 (ru) 2017-04-28
WO2011146494A1 (en) 2011-11-24
NZ603672A (en) 2015-01-30
CR20120630A (es) 2013-02-15
CA2799520C (en) 2016-09-13
US20130060028A1 (en) 2013-03-07
CN105837520A (zh) 2016-08-10
CN103003249A (zh) 2013-03-27
MA34301B1 (fr) 2013-06-01
EP2571857A1 (en) 2013-03-27
CA2799520A1 (en) 2011-11-24
BR112012030532A2 (pt) 2015-09-29
US20160347720A1 (en) 2016-12-01
EA201291235A1 (ru) 2013-04-30
JP2013530948A (ja) 2013-08-01
US9447052B2 (en) 2016-09-20
CN103003249B (zh) 2016-04-27
DOP2012000289A (es) 2013-04-15
PE20130318A1 (es) 2013-04-11
PH12012502247A1 (en) 2013-02-04
AR081399A1 (es) 2012-08-29
ZA201208631B (en) 2013-09-25

Similar Documents

Publication Publication Date Title
ECSP14033037A (es) Síntesis de compuestos heterocíclicos
CR20140534A (es) Proceso para la preparación de treprostinil y derivado de los mismos
AR083797A1 (es) Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
CL2017002283A1 (es) Formulaciones de anticuerpos y métodos (divisional de solicitud n°1081-2014)
CR20120011A (es) Inhibidores de bace
MX394214B (es) Sintesis de gamma-carbolinas fusionadas con heterociclo substituido.
ECSP14020478A (es) Formas polimórficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluoro-3-fenilquinazolin-4(3h)-ona
BR112013014943A2 (pt) compostos úteis para o tratamento de aids
UY34219A (es) Compuestos de 2-(2,4,5-anilino sustituido)pirimidina
GT201400023A (es) Derivados de 5-fluor-4-imino-3-(sustituido)-3,4-dihidropirimidin-2 (1h) ona
EP2780307A4 (en) METHOD FOR PRODUCING HYDROFLUOROLEFINES
HN2012000263A (es) Derivados n1-sulfonil-5-fluoropirimidinona
UY32863A (es) COMPUESTOS DE HEXAHIDROOXAZINOPTERINA PARA USO COMO INHIBIDORES DE mTOR
UY34108A (es) ?proceso para la fabricación de sustratos revestidos?.
CL2009001686A1 (es) Procedimiento de preparacion de agomelatina; y los compuestos intermediarios considerados.
MX2016004565A (es) Preparacion de derivados de hidroxi - bencilbenceno.
CL2011001405A1 (es) Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina.
EP2379493A4 (en) PROCESS FOR PRODUCING ASYMMETRIC BIS (THIOSEMICARBAZONE)
CL2012002082A1 (es) Proceso para la preparacion de lacosamida, por hidroximetilación; compuestos intermediarios.
UY34725A (es) Nuevos derivados de tienopirimidina, procesos para su preparación y sus usos terapéuticos.
ECSP11011485A (es) Espiro-epóxidos como productos intermedios.
CL2012000278A1 (es) Proceso para la obtencion de derivados de 5-trifluorometil-pirimidinas; y uno de los compuestos intermediarios considerados.
ECSP12011653A (es) Derivados de n1-acil-5-fluoropirimidinona
EA201891391A1 (ru) Диастереоселективный синтез фосфатных производных и пролекарства гемцитабина nuc-1031
CL2013003056A1 (es) Compuestos derivados de (fenil o piridin)-etinil-(piridin o pirimidin) sustituido; composición farmacéutica que los comprende; proceso de preparación de esto; y su uso en el tratamiento de la esquizofrenia o enfermedades cognitivas.